Martin Schrappe

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 247 publications

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Journal: Pediatric blood & cancer

Published: June 01, 2026

Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial.

Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial.

Journal: JCO oncology practice

Published: May 27, 2026

Catch them ALL?

Catch them ALL?

Journal: Blood

Published: March 19, 2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Journal: Blood

Published: February 13, 2026

Invasive mold infection in pediatric acute lymphoblastic leukemia-a detailed analysis of the clinical trial AIEOP-BFM ALL2009.

Invasive mold infection in pediatric acute lymphoblastic leukemia-a detailed analysis of the clinical trial AIEOP-BFM ALL2009.

Journal: Leukemia

Published: January 12, 2026

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.

Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.

Journal: British journal of haematology

Published: November 10, 2025

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 10, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere

Published: September 09, 2025

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Journal: HemaSphere

Published: August 14, 2025

PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure.

PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure.

Journal: European journal of drug metabolism and pharmacokinetics

Published: July 24, 2025

Incidence patterns and temporal trends of childhood cancer in Germany, 1980-2019: Forty years of childhood cancer registration in Germany.

Incidence patterns and temporal trends of childhood cancer in Germany, 1980-2019: Forty years of childhood cancer registration in Germany.

Journal: International journal of cancer

Published: June 04, 2025

Showing 1-12 of 247

Last Updated: 09/26/2026